PDK1 and esophageal squamous cell carcinoma: Furthermore, we found that parecoxib suppressed ESCC growth in heterotopic tumor models.<h4>Conclusion</h4>Parecoxib inhibits ESCC progression, including cell cycle, proliferation, invasion, and migration, via the PDK1-AKT signaling pathway.